Abstract:
The present invention provides a compound of the general formula (I) or a pharmaceutical salt thereof,  
                         
 
     wherein, when R 1  and R 2  are the same they are represented by ═O, ═N, —OR 9  (where R 9  is hydrogen, lower alkyl or benzyl), when R 1  and R 2  are different and one of R 1  and R 2  is represented by hydrogen, the other is represented by —R 5 —R 6 —, (where R 5  is —O—, —NH—, —NHCO—, or —NHSO 2 —, and where R 6  is hydrogen, lower alkyl, —Ph—R 7 , —(CH 2 )n—O—Ph—R 7 , (where n=1-6, R 7  is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or pyridyloxy), indolyl, N-oxidepyridyl, phthalimide, thienyl, or pyridyl); R 3  represents —COOH, —COOEt, —COOMe, —CH 2 N(OH)CHO, or —CONHOH; R 4  represents lower alkyl, thienyl, —Ph—R 8  (where R 9  represents hydroxy, lower alkyl, lower alkoxy, nitro, halogen, pyridyloxy, or phenyl group substituted hydrogen, lower alkyl, lower alkoxy, hydroxy, and halogen), and methods of making compounds within the class of the general formula (I).

Description:
BACKGROUND OF THE INVENTION  
         [0001]    1. Field of the Invention  
           [0002]    This invention relates to the pipecolinic acid and the derivative compounds thereof which have a Matrix Metalloproteinases (hereinafter shortened to MMPs) inhibitory function or the pharmaceutically permittable salt thereof and the production method thereof, further relates to a medicine composition containing said carboxylic acid and derivative compounds thereof or the salt thereof.  
           [0003]    2. Description of the Prior Art  
           [0004]    The MMPs are zinc dependent, calcium requiring enzymes that are involved in the degradation of extra cellular matrix. Under normal physiological conditions, the expression of the constitutive MMPs is low, and regulated by naturally occurring inhibitors termed TIMPs (tissue inhibitor of metalloproteinases). However, under pathological conditions such as rheumatoid and osteoarthritis, MMPs expression in cartilage is disregulated and resulted in over expression of MMPs which are not controlled by constitutive TIMPs. The level of the MMPs are high with enzymic activity and exceeding the level of the TIMPs. This condition leads to a loss of proteoglycan and collagen (J. Trzaskos, et al., Acta. Onthopaedica Scandinavia, 66, 150 (1995)).  
           [0005]    In addition, MMPs inhibitors are effective on treatment for corneal ulceration and tumor progression (R. P.Beckett et al., D.D.T., 1, 16 (1996)), and MMPs are playing important role in the pathogenesis of arteriosclerosis and restenosis after percutaneous transluminal coronary angioplasty (PTCA) (C. M. Dollery et al., Circ. Res.,77, 863 (1995)). Furthermore, application of MMPs inhibitors are effecitve on treatment for inflammatory bowel disease (Sylvia L., F. Pender et al., J. Immunol. ,158, 1582 (1997)). It is therapeutically useful to control the increased MMPs by MMPs inhibitors under these pathological conditions. Recently, a lot of MMPs inhibitors have been reported (R.Paul Beckett et al., Exp.Opin.Ther.Patents, 8 (3), 259-282 (1996)).  
           [0006]    3. Problems to be Solved by the Invention  
           [0007]    Though many reported MMPs inhibitors had excellent in vitro activity, these compounds had poor oral bioavailabilities. For example, the compounds had been performed intrapleural administration (Drug News &amp; Perspectives, 8 (4), 247 (1995)) or eye drops (Drug of the Future, 18, 1101 (1993)).  
           [0008]    The object of the present invention is the provision of pharmaceutical compositions useful as non-piptidic MMPs inhibitors being able to oral administration and a production method thereof.  
         DETAILED DESCRIPTION OF THE INVENTION  
         [0009]    The present invention provides a new pipecolinic acid derivative compound of general formula (I):  
                         
 
           [0010]    and its salt capable of being used for medical treatment. The lower alkyl mentioned in general formula (I) represents the straight or branched C 1 -C 6  alkyl group, so as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, isopentyl, cyclopropyl, cyclohexyl etc. The lower alkoxy represents alkoxy groups containing C 1 - C 6  carbon atom. The compound of general formula (I) contain several isomers, so this invention contains these isomers.  
           [0011]    In the compound of general formula (I), pharmacologically, R 3  prefers —COOH and CONHOH. R 1  and R 2  prefer that one of two groups is hydrogen and the other is —R 5  -R 6 .  
           [0012]    In this case, R 5  prefers —NH— and —NHCO—, and R 6  prefers phenyl group that is substituted by methyl, pyridyl, methoxy, halogen, or nitro. R 4  prefers phenyl and biphenyl which are substituted by methoxy, halogen, or nitro, respectively. Furthermore, the compound which containing phenyl groups exhibit non-selective inhibition, and the compound which containing biphenyl groups exhibit selective inhibition for MMP-2 and MMP-9.  
           [0013]    In the isomer, (2R, 4R)-configuration is preferred.  
           [0014]    The compound of general formula (I) can be obtained as follows. 4-Hydroxy-pipecolinic acid methyl ester is used as starting material, and the compound has (2R, 4S)- and (2S, 4R)- isomer. Both isomers are used for the preparetion of the compound of general formula (I), and the isomer of general formula (I) can be obtained.  
           [0015]    (A) In the case of R 1  is hydrogen atom, R 2  is —OH, and R 3  is —COOH in the compounds of general formula (I), it is prepared by the following reactions.  
                         
 
           [0016]    (wherein R 4  is the same as mentioned above.)  
           [0017]    4-hydroxypipecolinic acid (II) is reacted with sulfonyl chloride using organic base for example triethylamine, pyridine, etc, or mineral base for example sodium carbonate, potassium carbonate, etc and THF/H 2 O, etc as a mixed solvent to yield compound (III). Then the desired compound (XVIII) is obtained by hydrolysis of the compound (III) using alkali - metal hydroxide (NaOH, KOH or LiOH).  
           [0018]    (B) In case of R 1  is hydrogen atom, R 2  is —OH, and R 3  is —CONHOH in the compounds of general formula (I), it is prepared by the following reactions.  
                         
 
           [0019]    (wherein R 4  is the same as mentioned above.)  
           [0020]    The desired compound (XIX) is obtained by the reaction of the compound (III) and hydroxylamine hydrochloride salt using potassium hydroxide in THF.  
           [0021]    (C) In the case of R 1 .and.R 2  are ═O, R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0022]    (wherein R 4  is the same as mentioned above.)  
           [0023]    The compound of general formula (III) is reacted with oxidant for example PDC, PCC, etc in CH 2 Cl 2 , DMF, etc as a solvent to yield the compound of general formula (VIII).  
           [0024]    The desired compound of general formula (XX) is obtained by alkali hydrolisys of that compound.  
           [0025]    (D) In case of R 1  and R 2  are ═O, and R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0026]    (wherein R 4  is the same as mentioned above.)  
           [0027]    The compound of the general formula (XX) is reacted with hydroxylamine hydrochloride salt using coupling reagents, for example WSCDI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide . HCl salt), DCC (1,3-dicyclohexylcarbodiimide), DPPA (diphenylphosphorylazide), DEPC (diethylphosphoryl cyanide), etc, and in the presence of the base, for example NMM (N-methylmorpholine), triethylamine, etc, in methlenechloride, THF, DMF, etc as a soluvent, to yield the desired compound of the general formula (XXI).  
           [0028]    (E) In case of R 1  is hydrogen atom, R 2  is —NH 2 , and R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0029]    (wherein R 4  is the same as mentioned above.)  
           [0030]    The compound of general formula (III) is reacted with MsCl (methanesulfonyl chloride) or TsCl (p-toluenesulfonyl chloride ) in the precense of the base for example triethylamine, pyridine, etc, in THF, CH 2 Cl 2 , DMF, etc as a solvent to yield the compound of general formula (IV), then it is reacted with sodium azide in THF, DMF, etc as a solvent to yield the compound of general formula (V). Subsequently, The compound of general formula (V) is converted to the compound of general formula (VI) by hydrogenation with Pd in methnol, THF, etc as a solvent under H 2  atomosphere, or, with triphenylphosphine in THF/H 2 O mixed solvent, then it is hydrolyzed to yield the compound of general formula (XXII).  
           [0031]    (F) In case of R 1  is hydrogen atom, R 2  is —NH 2 , and R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0032]    (wherein R 4  is the same as mentioned above.)  
           [0033]    The compound of the general formula (VI) is reacted with the THF solution that disolved hydroxylamine hydrochloride salt and potassium hydroxide in THF solution to yield the desired compound of the general formula (XXIII).  
           [0034]    (G) In case of R 1  is hydrogen atom, R 2  is —OH, and R 3  is —COOH in the compounds of the general formula (I)which is isomer of the compound on preparetion of method (A), it is prepared by the following reactions.  
                         
 
           [0035]    (wherein R 4  is the same as mentioned above.)  
           [0036]    The compound of the general formula (IV) is reacted with cesium acetate in THF, toluene, etc as a soluvent to yield the compound of the general formula (XXIV), then it is reacted with sodium methoxide in methanol to yield the desired compound of the general formula (III).  
           [0037]    (H) In case of R 1  is hydrogen atom, R 2  is —NHCO—R 6,  and R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0038]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0039]    The compound of the general formula (VI) is reacted with acid chloride in the presence of organic base, for example triethylamine, pyridine, etc. or mineral base, for example sodium carbonate, potassium carbonate, etc in CH 2 Cl 2 , CHCl 3 , etc as a solvent to yield the compound of the general formula (XIII). Then it is hydrolyzed with lithium hydroxide to yield the desired compound of the general formula (XXV).  
           [0040]    (I) In case of R 1  is hydrogen atom, R 2  is —NHCO—R 6 , R 3  is —COOH, and R 4  is —Ph—R 8  in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0041]    (wherein R 6  is the same as mentioned above, R 8  is H, lower alkyl, lower alcoxy, hydroxy, or halogen substituted phenyl group, X is halogen)  
           [0042]    The compound of the general formula (XXXXVII) is subjected to cross-coupling reaction with a boronic acid using palladium or nickel catalyst to yield the compound of the general formula (XXXXVIII) (A. Suzuki, Synth. Org. Chem. Jpn., 1988, 46, 848.; E. Negishi, J. Org. Chem., 1977, 42, 1821.; J. K. Stille, J. Org. Chem., 1987, 52, 422.). Tetrakis (triphenylphosphine) palladium, palladium chloride, palladium acetate, etc is used as the catalyst, and the reaction carried out in the presence of the base, for example sodium carbonate, potassium carbonate, cesium carbonate, etc in toluene, DMF, or H 2 O. Then the compound of general formula (XXXXVIII) is hydrolyzed with lithium hydroxide to yield the desired compound of the general formula (XXXXIX).  
           [0043]    (J) In case of R 1  is hydrogen atom, R 2  is —NHCO—R 6 , and R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0044]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0045]    The compound of the general formula (XXV) is reacted with hydroxylamine hydrochloride salt using coupling reagents, for example WSCDI, DCC, DPPA, DEPC, etc, and in the presence of the base, for example NMM (N - methylmorpholine), triethylamine, etc, in methlenechloride, THF, DMF, etc as a soluvent, to yield the desired compound of the general formula (XXVIII).  
           [0046]    The other method, the compound of the general formula (XXV) is condenced with O-benzylhydroxylamine hydrochloride salt instead of hydroxylamine hydrochloride salt using tha same condition, followed by debenzylation with palladium on carbone to yield the desired compound of the general formula (XXVIII).  
                         
 
           [0047]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0048]    (K) In case of R 1  is hydrogen atom, R 2  is —NHSO 2 —R 6 , and R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0049]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0050]    The compound of the general formula (VI) is reacted with sulfonyl chloride in the presence of organic base, for example triethylamine, pyridine, etc. or mineral base, for example sodium carbonate, potassium carbonate, etc in CH 2 Cl 2 , CHCl 3 , etc as a solvent to yield the compound of the general formula (XXIX). Then it is hydrolyzed with lithium hydroxide to yield the desired compound of the general formula (XXX).  
           [0051]    (L) In case of R 1  is hydrogen atom, R 2  is —NHSO 2 —R 6 , and R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0052]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0053]    The compound of the general formula (XXX) is reacted with hydroxylamine hydrochloride salt using coupling reagents, for example WSCDI, DCC, DPPA, DEPC, etc, and in the presence of the base, for example NMM (N-methylmorpholine), triethylamine, etc, in methlenechloride, THF, DMF, etc as a soluvent, to yield the desired compound of the general formula (XXXI).  
           [0054]    The other method, the compound of the general formula (XXX) is condenced with O-benzylhydroxylamine hydrochloride salt instead of hydroxylamine hydrochloride salt using tha same condition, then it is debenzylated with palladium on carbone to yield the desired compound of the general formula (XXXI).  
                         
 
           [0055]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0056]    (M) In case of R 1  is hydrogen atom, R 2  is —NH—R 6 , and R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0057]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0058]    The compound of the general formula (VI) is reacted with aldehyde using sodium borohydride, cyano borohydride, or palladium on carbone in methanol, THF, etc as a soluvent to yield the compound of the general formula (XXXII). Then it is hydrolyzed with lithium hydroxide to yield the desired compound of the general formula (XXXIII).  
           [0059]    (N) In case of R 1  is hydrogen atom, R 2  is —NH—R 6 , and R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0060]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0061]    The compound of the general formula (XXXII) is reacted with hydroxylamine hydrochloride salt and potassium hydroxide in THF solution, to yield the desired compound of the general formula (XXXIV).  
           [0062]    (O) In case of R 1  and R 2  are ═N—OR 9 , R 3  is —COOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0063]    (wherein R 4  and R 9  are the same as mentioned above.)  
           [0064]    The compound of the general formula (VIII) is reacted with R 9 O—NH 2  HCl (R 9  is methyl or benzyl), in the presence of the base, for example triethylamine, etc to yield the compound of the general formula (IX). Then it is hydrolyzed with lithium hydroxide to yield the desired compound of the general formula (XXVI).  
           [0065]    (P) In case of R 1  and R 2  are ═N—OR 9 , R 3  is —CONHOH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0066]    The compound of the general formula (XXVI) is reacted with hydroxylamine hydrochloride salt using coupling reagents, for example WSCDI, DCC, DPPA, DEPC, etc, and in the presence of the base, for example NMM (N-methylmorpholine), triethylamine, etc, in methlenechloride, THF, DMF, etc as a soluvent, to yield the desired compound of the general formula (XXVII).  
           [0067]    (Q) In case of R 1  is hydrogen atom, R 2  is —NHCO—R 6 , and R 3  is —CH 2 N(OH)COH in the compounds of the general formula (I), it is prepared by the following reactions.  
                         
 
           [0068]    (wherein R 4  and R 6  are the same as mentioned above.)  
           [0069]    The compound of the general formula (XIII) is reduced with lithium borohydride, etc as a reductant in THF to yield the compound of the general formula (XIV), then it is done swern oxidation to yield the compound of the general formula (XV). Subsecuently, the compound of the general formula (XV) is reacted with hydroxylamine hydrochloride salt using sodium borohydride, cyano borohydride, or palladium on carbone in methanol, THF, etc as a soluvent to yield the compound of the general formula (XVI).Furthermore, it is reacted with formic acid using coupling reagent such as DCC, WSCDI, etc in THF, etc as a solvent to yield the desired compound of the general formula (XVII).  
           [0070]    The compounds related to the general formula (I) are exemplified as follows.  
           [0071]    1. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 1)  
           [0072]    2. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-[5-(4-methoxyphenoxy) pentanoylamino)-piperidine (Compound 2)  
           [0073]    3. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(4-methoxybenzoylamino)- piperidine (Compound 3)  
           [0074]    4. (2R, 4R)-2-Carboxy-4-(4-methoxybenzoylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl)-piperidine (Compound 4)  
           [0075]    5. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 5)  
           [0076]    6. (2R, 4R)-2-Carboxy-4-(4-methoxybenzoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 6)  
           [0077]    7. (2R, 4R)-2-Carboxy-4-(4-methylpentanoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 7)  
           [0078]    8. (2R, 4R)-1-(4-Bromobenzenesulfonyl)-2-carboxy-4-(4-methylpentanoylamino)-piperidine (Compound 8)  
           [0079]    9. (2R, 4R)-1-(4-Bromobenzenesulfonyl)-2-carboxy-4-(4-methoxybenzoylamino)-piperidine (Compound 9)  
           [0080]    10. (2R, 4R)-2-Carboxy-1-[3-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 10)  
           [0081]    11. (2R, 4R)-2-Carboxy-1-[3-(4-hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 11)  
           [0082]    12. (2R, 4R)-2-Carboxy-1-[2-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methyl -pentanoylamino)-piperidine (Compound 12)  
           [0083]    13. (2R, 4R)-2-Carboxy-1-[2-(4- hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 13)  
           [0084]    14. (2R, 4R)-4-Benzylamino -2-carboxy- -1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 14)  
           [0085]    15. (2R, 4R)-2-Carboxy-1-[4-(4- hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 15)  
           [0086]    16. (2R, 4R)-2-Carboxy-4-(4-methoxybenzenesulfonylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 16)  
           [0087]    17. (2R, 4R)-4-Benzoylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]- piperidine (Compound 17)  
           [0088]    18. (2R, 4R)-4-Benzoylamino-2-carboxy-1-[4-(4-hydroxyphenyl)benzenesulfonyl]-piperidine (Compound 18)  
           [0089]    19. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentylamino)-piperidine (Compound 19)  
           [0090]    20. (2R, 4R)-2-Carboxy-4-(4-methoxybenzylamino)benzenesulfonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 20)  
           [0091]    21. (2R, 4R)-2-Carboxy-1-(4-hydroxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 21)  
           [0092]    22. (2R, 4R)-4-Acetylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 22)  
           [0093]    23. (2R, 4R)-4-Acetylamino-2-carboxy-1-[4-(4-hydroxyphenyl)benzenesulfonyl]-piperidine (Compound 23)  
           [0094]    24. (2R, 4R)-4-Acetylamino-2-carboxy-1-(4-methoxybenzenesulfonyl]-piperidine (Compound 24)  
           [0095]    25. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-phtalimidyl-piperidine (Compound 25)  
           [0096]    26. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-phtalimidyl-piperidine (Compound 26)  
           [0097]    27. (2R, 4R)-2-Carboxy-4-ethylamino-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 27)  
           [0098]    28. (2R, 4R)-2-Carboxy-4-diethylamino-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 28)  
           [0099]    29. (2R, 4R)-2-Carboxy-4-(4-methylpentylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 29)  
           [0100]    30. (2R, 4R)-2-Carboxy-1-[4-(4-chlorophenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 30)  
           [0101]    31. (2R, 4R)-4-Acetylamino-2-carboxy-1-[4-(4- chlorophenyl)benzenesulfonyl]-piperidine (Compound 31)  
           [0102]    32. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(2-thiophenecarbonylamino)-piperidine (Compound 32)  
           [0103]    33. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(2-pyridinecarbonylamino)-piperidine (Compound 33)  
           [0104]    34. (2R, 4R)-2-Carboxy-1-[4-(4- chlorophenyl)benzenesulfonyl]-4-(2-pyridinecarbonylamino)-piperidine (Compound 34)  
           [0105]    35. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-nitrobenzoyllamino)-piperidine (Compound 35)  
           [0106]    36. (2R, 4R)-2-Carboxy-4-(3-indolecarbonylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 36)  
           [0107]    37. (2R, 4R)-2-Carboxy-4-(4-methylpentanoylamino)-1-(4-nitrobenzenesulfonyl)-piperidine (Compound 37)  
           [0108]    38. (2R, 4R)-2-Carboxy-4-(4-methylpentanoylamino)-1-[4-(4-nitrophenyl) benzenesulfonyl]-piperidine (Compound 38)  
           [0109]    39. (2R, 4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(pyridin-N-oxide-2-yl) carbonylamino-piperidine (Compound 39)  
           [0110]    40. (2S, 4S)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-[5-(4-methoxyphenoxy) pentanoylamino]-piperidine (Compound 40)  
           [0111]    41. (2S, 4S)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 41)  
           [0112]    42. (2S, 4S)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(4-methoxybenzoylamino)-piperidine (Compound 42)  
           [0113]    43. (2S, 4S)-4-Acetylamino-2-carboxy-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 43)  
           [0114]    44. (2R, 4S)-4-Acetylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 44)  
           [0115]    45. (2R, 4R)-2- Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 45)  
           [0116]    46. (2R, 4R)-2- Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-[5-(4-methoxyphenoxy) pentanoylamino]-piperidine (Compound 46)  
           [0117]    47. (2R, 4R)-2- Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-(4-methoxybenzoylamino)-piperidine (Compound 47)  
           [0118]    48. (2R, 4R)-2- Hydroxyaminocarbonyl-4-(4-methoxybenzoylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 48)  
           [0119]    49. (2R, 4R)-2- Hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 49)  
           [0120]    50. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methoxybenzoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 50)  
           [0121]    51. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methylpentanoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 51)  
           [0122]    52. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[3-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 52)  
           [0123]    53. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[3-(4-hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 53)  
           [0124]    54. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[2-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 54)  
           [0125]    55. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[2-(4-hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 55)  
           [0126]    56. (2R, 4R)-4-Benzylamino-2-hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 56)  
           [0127]    57. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[4-(4-hydroxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino) piperidine (Compound 57)  
           [0128]    58. (2R, 4R)-2-Hydroxyaminocarbonyl-1-methanesulfonyl -4-(pyridin -2-yl) carbonylamino-piperidine (Compound 58)  
           [0129]    59. (2R, 4R)-4-Benzoylamino-2-hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 59)  
           [0130]    60. (2R, 4R)-4-Benzoylamino-2-hydroxyaminocarbonyl-1-[4-(4-hydroxyphenyl) benzenesulfonyl]-piperidine (Compound 60)  
           [0131]    61. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentylamino)-piperidine (Compound 61)  
           [0132]    62. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methoxybenzylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 62)  
           [0133]    63. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[4-(4-hydroxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 63)  
           [0134]    64. (2R, 4R)-4-Acetylamino-2-hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 64)  
           [0135]    65. (2R, 4R)-4-Acetylamino-2-hydroxyaminocarbonyl-1-[4-(4-hydroxyphenyl) benzenesulfonyl]-piperidine (Compound 65)  
           [0136]    66. (2R, 4R)-4-Acetylamino-2-hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 66)  
           [0137]    67. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methylpentanoylamino)-1-[4-(4-nitrophenyl) benzenesulfonyl]-piperidine (Compound 67)  
           [0138]    68. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(pyridyl -2-yl) carbonylamino-piperidine (Compound 68)  
           [0139]    69. (2R, 4R)-2-Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-(pyridyl -2-yl) carbonylamino-piperidine (Compound 69)  
           [0140]    70. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methylpentylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 70)  
           [0141]    71. (2R, 4R)-1-[4-(4-Chlorohenyl)benzenesulfonyl]-2-hydroxyaminocarbonyl-4-(4-methylpentanoylamino)-piperidine (Compound 71)  
           [0142]    72. (2R, 4R)-4-Acetylamino-1-[4-(4-chlorohenyl)benzenesulfonyl]-2-hydroxyaminocarbonyl-piperidine (Compound 72)  
           [0143]    73. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(2-pyridinecarbonylamino-piperidine (Compound 73)  
           [0144]    74. (2R, 4R)-1-[4-(4-Chlorophenyl)benzenesulfonyl]-2-hydroxyaminocarbonyl-4-(2-pyridinecarbonylamino)-piperidine (Compound 74)  
           [0145]    75. (2R, 4R)-2-Hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-nitrobenzoylamino)-piperidine (Compound 75)  
           [0146]    76. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(3-indolecarbonylamino)-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 76)  
           [0147]    77. (2R, 4R)-2-Hydroxyaminocarbonyl-4-(4-methylpentanoylamino)-1-(4-nitrobenzenesulfonyl)-piperidine (Compound 77)  
           [0148]    78. (2S, 4S)-2-Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-[5-(4-methoxyphenoxy) pentanoylamino]-piperidine (Compound 78)  
           [0149]    79. (2S, 4S)-2-Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-(4-methylpentanoylamino)-piperidine (Compound 79)  
           [0150]    80. (2S, 4S)-2-Hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-4-(4-methoxybenzoylamino)-piperidine (Compound 80)  
           [0151]    81. (2S, 4S)-4-Acetylamino-2-hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 81)  
           [0152]    82. (2R, 4S)-4-Acetylamino-2-hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 82)  
           [0153]    83. (2R, 4R)-4-Acetylamino-1-[4-(4- chlorophenyl)benzenesulfonyl]2-(N′-formyl-hydroxyamino) methyl-piperidine (Compound 83)  
           [0154]    84. (2R, 4R)-1-[4-(4-Chlorophenyl)benzenesulfonyl]-2-(N′-formyl -hydroxyamino) methyl-4-(4-methylpentanoylamino)-piperidine (Compound 84)  
           [0155]    85. (2R, 4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(pyridyl-N-oxide-2-yl) carbonylamino-piperidine (Compound 85)  
           [0156]    86. (2R, 4R)-2-Carboxy-1-(4-chlorobenzenesulfonyl)-4-(pyridyl-N- oxide-2-yl) carbonylamino-piperidine (Compound 86)  
           [0157]    87. (2R, 4R)-2-Carboxy-1-methanesulfonyl-4-(pyridyl-N-oxide-2-yl) carbonylamino-piperidine (Compound 87)  
           [0158]    88. (2R, 4R)-2-Carboxy-1-dimethylaminosulfonyl-4-(pyridyl-N-oxide-2-yl) carbonylamino-piperidine (Compound 88)  
           [0159]    89. (2R, 4R)-2-Carboxy-1-[4-(4-chlorophenyl)benzenesulfonyl]-4-(pyridyl-N-oxide -2-yl) carbonylamino-piperidine (Compound 89)  
           [0160]    The carboxylic acid derivatives in this invention is useful as pharmaceutical compositions using to treatment and/or prevention for disease related to destruction of extra cellular matrix induced by MMPs. They can be administered orally in the form of tablets, capsules, granules and syrups, and also can be administered intravenously. An effective dosage of the compounds is from 10 to 1000 mg once to several times a day for adults, though it may be adjusted depending on age and symptoms.  
         PHARMACOLOGICAL EXAMINATION  
         [0161]    The compound of general formula (I) in the invention is a potent inhibitor of MMPs. A pharmacological examination is described as follows.  
           [0162]    Examination 1: MMP-1 (type I collagenase) inhibitory activities.  
           [0163]    Inhibitory activities of MMP-1 (type I collagenase) activities were estimated by enzyme assay using human fibroblasts derived MMP-1 (Yagai Co. Ltd.) as enzyme, and MOCAc-Pro-Leu-Gly-Leu-A 2 pr(Dnp)-Ala-Arg-NH 2  (Peptide Research Center, 3163-v) as substrate. Thus, MMP-1 (0.01 U/ml), test compound (10 −10 ˜10 −5  M), and the substrate (10 μM) were incubated in 50 mM Tris-HCl buffer (pH 7.4) containing 0.2M NaCl, 10 mM CaCl 2 , 0.02% NaN 3 , and 0.05% Brij 35 at 37° C. for 4 h. The reaction was stopped by adding of 4 volumes of sodium acetate buffer (pH 4.0), and the degradation of substrate was calculated by measurement with a fluorescence intensity (λ ex 328 nm, λ em 393 nm). Inhibition of degradation of substrate in the presence of compound was determined by comparison with the degradation percent of substrate in the absence of compound, and concentration of 50% inhibition (IC 50  value) was calculated.  
           [0164]    Examination 2: MMP-2 (gelatinase A) and MMP-9 (gelatinase B) inhibitory activities.  
           [0165]    Pro MMP-2 was obtained from culture medium separated from human pro-MMP-2 cDNA tranfected COS-1 cells. Pro MMP-2 activated by 1 mM (4-aminophenyl) mercury acetic acid and MMP-9, derived human fibrosarcome (Yagai Co. Ltd.), were used as enzyme respectively. Inhibition of both enzyme activities were estimated by enzyme assay using MOCAc-Pro-Leu-Gly-Leu-A 2 pr(Dnp)-Ala-Arg-NH 2  (Peptide Research Center, 3163-v) as substrate. Thus, MMP-2 or MMP-9 (0.01 U/ml), test compound (several concentrations), and the substrate (10 μM) were incubated in 50 mM Tris - HCl buffer (pH 7.4) containing 0.2M NaCl, 10 mM CaCl 2 , 0.02% NaN 3 , and 0.05% Brij 35 at 42° C. for 2 h (MMP-2), 3 h (MMP-9) respectively. Inhibition of degradation of substrate in the presence of compound was determined by comparison with the degradation of substrate in the absence of compound, and concentration of 50% inhibition (IC 50  value) was calculated.  
           [0166]    Examination 3: Δ MT1-MMP (Δ MMP-14) inhibitory activities.  
           [0167]    ProMT1-MMP cDNA encoded extracellular domain of pro Δ MT1-MMP was tranfected E. coli BL21DE3, pro Δ MT1-MMP collected as inclusion body was solved using 8M urea, and it was pulified by ion exchenge column chlomatography. Inhibition of enzyme activities were estimated by enzyme assay using activated Δ MT1-MMP, obtained from activation of pro Δ MT1-MMP by 10 μ/ml tripsine, and MOCAc-Pro-Leu-Gly-Leu-A 2 pr(Dnp)-Ala-Arg-NH 2  (Peptide Research Center, 3163-v) as substrate. Thus, Δ MT1-MMP, test compound (several concentrations), and the substrate (10 μM) were incubated in 50 mM Tris - HCl buffer (pH 7.4) containing 0.2M NaCl, 10 mM CaCl 2 , 0.02% NaN 3 , 0.05% Brij 35, and 10 μM leuipeputine at 37° C. for 30 min. The reaction was stopped by adding of 4 volumes of sodium acetate buffer (pH 4.0), and the degradation of substrate was calculated by measurement with a fluorescence intensity (λ ex 328 nm, λ em 393 nm). Inhibition of degradation of substrate in the presence of compound was determined by comparison with the degradation of substrate in the absence of compound, and concentration of 50% inhibition (IC 50  value) was calculated.  
           [0168]    The results are described in table 1, 2.  
                               TABLE 1                       Chem.                       No.   MMP-1   MMP-2   MMP-9   ΔMMP-14                   45   45.3% (10 −5 M)   1.7 × 10 −9 M   1.4 × 10 −9 M   1.6 × 10 −8 M       46   7.6 × 10 −6 M   1.5 × 10 −9 M       8.8 × 10 −10 M   4.3 × 10 −9 M       47   5.5 × 10 −6 M   1.7 × 10 −9 M   1.3 × 10 −9 M   3.2 × 10 −9 M       48   35.5% (10 −5 M)       5.5 × 10 −10 M       4.0 × 10 −10 M   3.1 × 10 −7 M       49   2.6 × 10 −6 M       2.5 × 10 −10 M       2.6 × 10 −10 M   1.3 × 10 −7 M       50   8.4 × 10 −6 M   7.3 × 10 −8 M   4.4 × 10 −8 M   3.5 × 10 −8 M       51   6.5 × 10 −9 M   8.0 × 10 −8 M   7.5 × 10 −8 M   3.1 × 10 −8 M       52   48.9% (10 −5 M)   2.1 × 10 −7 M   4.2 × 10 −7 M   7.9 × 10 −8 M       53   53.0% (10 −5 M)   9.6 × 10 −7 M   6.9 × 10 −6 M   2.0 × 10 −6 M       54   45.8% (10 −5 M)   3.8 × 10 −7 M   1.8 × 10 −6 M   2.0 × 10 −7 M       55   29.5% (10 −5 M)   2.4 × 10 −6 M   34.8% (10 −5 M)   3.0 × 10 −6 M       56   1.3 × 10 −6 M       4.9 × 10 −10 M       3.6 × 10 −10 M   1.6 × 10 −8 M       57   4.6 × 10 −7 M   1.8 × 10 −9 M   1.1 × 10 −8 M   1.0 × 10 −7 M       59   57.6% (10 −5 M)   1.8 × 10 −7 M   1.1 × 10 −8 M   9.5 × 10 −8 M       60   4.9 × 10 −6 M   2.9 × 10 −9 M   8.9 × 10 −7 M   1.3 × 10 −7 M       61   44.6% (10 −5 M)   2.7 × 10 −9 M   1.9 × 10 −8 M   4.9 × 10 −8 M       62   8.7 × 10 −7 M       9.3 × 10 −10 M   3.2 × 10 −9 M   4.5 × 10 −8 M       63   5.1 × 10 −7 M   2.8 × 10 −8 M   3.1 × 10 −8 M   1.7 × 10 −8 M       64   6.5 × 10 −7 M       9.1 × 10 −10 M       7.2 × 10 −10 M   8.9 × 10 −9 M       65   8.7 × 10 −7 M   4.8 × 10 −9 M   5.1 × 10 −8 M   2.3 × 10 −8 M       66   5.3 × 10 −7 M   4.2 × 10 −9 M   8.6 × 10 −9 M   2.1 × 10 −9 M       67   1.2 × 10 −6 M   2.2 × 10 −8 M   3.6 × 10 −8 M   1.5 × 10 −6 M       69   4.1 × 10 −8 M   2.5 × 10 −9 M   1.4 × 10 −9 M   2.4 × 10 −8 M       70   5.6 × 10 −6 M   7.4 × 10 −7 M   8.3 × 10 −8 M   3.8 × 10 −7 M       71   6.4 × 10 −7 M   1.9 × 10 −8 M   3.4 × 10 −9 M   2.9 × 10 −7 M       72   3.7 × 10 −8 M   3.0 × 10 −9 M   1.1 × 10 −9 M   2.3 × 10 −8 M       73   1.2 × 10 −6 M   6.0 × 10 −9 M   4.0 × 10 −9 M   3.6 × 10 −9 M       74   48.9% (10 −5 M)   5.2 × 10 −9 M   1.3 × 10 −8 M   7.4 × 10 −8 M       75   2.5 × 10 −6 M   1.5 × 10 −8 M   1.6 × 10 −8 M   8.9 × 10 −7 M       76   12.9% (10 −5 M)   1.2 × 10 −8 M   2.1 × 10 −8 M   9.6 × 10 −8 M       77   32.2% (10 −5 M)   4.8 × 10 −7 M   7.4 × 10 −7 M   2.3 × 10 −6 M       78   31.1% (10 −5 M)   5.0 × 10 −7 M   4.5 × 10 −7 M   3.0 × 10 −7 M       79   NE (10 −5 M)   7.6 × 10 −6 M   23.3% (10 −5 M)   5.0 × 10 −6 M       81   37.3% (10 −5 M)   2.2 × 10 −7 M   3.9 × 10 −7 M   8.9 × 10 −8 M       82   NE (10 −5 M)   7.4 × 10 −7 M   4.4 × 10 −7 M   1.3 × 10 −6 M       89   14.0% (10 −5 M)   2.8 × 10 −8 M   2.0 × 10 −7 M   7.0 × 10 −6 M                                  
 
           [0169]    [0169]                               TABLE 2                       Chem.                       No.   MMP-1   MMP-2   MMP-9   ΔMMP-14                   45   45.3% (10 −5 M)   1.7 × 10 −9 M   1.4 × 10 −9 M   1.6 × 10 −8 M       46   7.6 × 10 −6 M   1.5 × 10 −9 M       8.8 × 10 −10 M   4.3 × 10 −9 M       47   5.5 × 10 −6 M   1.7 × 10 −9 M   1.3 × 10 −9 M   3.2 × 10 −9 M       48   35.5% (10 −5 M)       5.5 × 10 −10 M       4.0 × 10 −10 M   3.1 × 10 −7 M       49   2.6 × 10 −6 M       2.5 × 10 −10 M       2.6 × 10 −10 M   1.3 × 10 −7 M       50   8.4 × 10 −6 M   7.3 × 10 −8 M   4.4 × 10 −8 M   3.5 × 10 −8 M       51   6.5 × 10 −9 M   8.0 × 10 −8 M   7.5 × 10 −8 M   3.1 × 10 −8 M       52   48.9% (10 −5 M)   2.1 × 10 −7 M   4.2 × 10 −7 M   7.9 × 10 −8 M       53   53.0% (10 −5 M)   9.6 × 10 −7 M   6.9 × 10 −6 M   2.0 × 10 −6 M       54   45.8% (10 −5 M)   3.8 × 10 −7 M   1.8 × 10 −6 M   2.0 × 10 −7 M       55   29.5% (10 −5 M)   2.4 × 10 −6 M   34.8% (10 −5 M)   3.0 × 10 −6 M       56   1.3 × 10 −6 M       4.9 × 10 −10 M       3.6 × 10 −10 M   1.6 × 10 −8 M       57   4.6 × 10 −7 M   1.8 × 10 −9 M   1.1 × 10 −8 M   1.0 × 10 −7 M       59   57.6% (10 −5 M)   1.8 × 10 −7 M   1.1 × 10 −8 M   9.5 × 10 −8 M       60   4.9 × 10 −6 M   2.9 × 10 −9 M   8.9 × 10 −7 M   1.3 × 10 −7 M       61   44.6% (10 −5 M)   2.7 × 10 −9 M   1.9 × 10 −8 M   4.9 × 10 −8 M       62   8.7 × 10 −7 M       9.3 × 10 −10 M   3.2 × 10 −9 M   4.5 × 10 −8 M       63   5.1 × 10 −7 M   2.8 × 10 −8 M   3.1 × 10 −8 M   1.7 × 10 −8 M       64   6.5 × 10 −7 M       9.1 × 10 −10 M       7.2 × 10 −10 M   8.9 × 10 −9 M       65   8.7 × 10 −7 M   4.8 × 10 −9 M   5.1 × 10 −8 M   2.3 × 10 −8 M       66   5.3 × 10 −7 M   4.2 × 10 −9 M   8.6 × 10 −9 M   2.1 × 10 −9 M       67   1.2 × 10 −6 M   2.2 × 10 −8 M   3.6 × 10 −8 M   1.5 × 10 −6 M       69   4.1 × 10 −8 M   2.5 × 10 −9 M   1.4 × 10 −9 M   2.4 × 10 −8 M       70   5.6 × 10 −6 M   7.4 × 10 −7 M   8.3 × 10 −8 M   3.8 × 10 −7 M       71   6.4 × 10 −7 M   1.9 × 10 −8 M   3.4 × 10 −9 M   2.9 × 10 −7 M       72   3.7 × 10 −8 M   3.0 × 10 −9 M   1.1 × 10 −9 M   2.3 × 10 −8 M       73   1.2 × 10 −6 M   6.0 × 10 −9 M   4.0 × 10 −9 M   3.6 × 10 −9 M       74   48.9% (10 −5 M)   5.2 × 10 −9 M   1.3 × 10 −8 M   7.4 × 10 −8 M       75   2.5 × 10 −6 M   1.5 × 10 −8 M   1.6 × 10 −8 M   8.9 × 10 −7 M       76   12.9% (10 −5 M)   1.2 × 10 −8 M   2.1 × 10 −8 M   9.6 × 10 −8 M       77   32.2% (10 −5 M)   4.8 × 10 −7 M   7.4 × 10 −7 M   2.3 × 10 −6 M       78   31.1% (10 −5 M)   5.0 × 10 −7 M   4.5 × 10 −7 M   3.0 × 10 −7 M       79   NE (10 −5 M)   7.6 × 10 −6 M   23.3% (10 −5 M)   5.0 × 10 −6 M       81   37.3% (10 −5 M)   2.2 × 10 −7 M   3.9 × 10 −7 M   8.9 × 10 −8 M       82   NE (10 −5 M)   7.4 × 10 −7 M   4.4 × 10 −7 M   1.3 × 10 −6 M       89   14.0% (10 −5 M)   2.8 × 10 −8 M   2.0 × 10 −7 M   7.0 × 10 −6 M                                    
       
    
    
     EXAMPLE  
       [0170]    The following examples are provided only for the purpose of the compound and not restrict the disclosed invention.  
         [0171]    Example: 1 (2R,4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(4-methylpentanoylamino)-piperidine (Compound 5)  
         [0172]    (a) (2R,4S)-4-Hydroxy-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
         [0173]    (2R,4S)-4-Hydroxypipecolinic acid methyl ester (2.8 g) was dissolved in THF/H 2 O (2:1, 45 mL), then NaHCO 3  (1.63 g) and 4-(4-methoxyphenyl)benzenesulfonylchloride (5.47 g) were added at 0° C., and the mixture was stirred for 3 h at room temperature.  
                         
 
         [0174]    The reaction mixture was concentrated in vacuo, then the residue was extracted with ethyl acetate (100 mL×2) followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated. The residue was purified by silica gel column chromatography using AcOEt:n-hexane (2:1), the object compound was obtained as a white solid (5.45 g).  
         [0175]    IR(cm −1 ): 3514,1746,1608,1341,1296,1197,1152,1080  
         [0176]    MS(m/z): 405(M + ),373,329,247,183,139,82,55(BP)  
         [0177]    [0177] 1 H-NMR(CDCl 3 ) 1.74-1.77(2H,m,C3-H,C5-H),1.97-2.03(1H,m,C5-H),2.43(1H,brd,C3-H), 3.54(3H,s,CO 2 CH 3 ),3.57-3.61(1H,m,C6-H),3.86(3H,s,OCH 3 ),4.15(1H,brs,C4-H),4.74(1H, d,C2-H),7.00(2H,d,aromatic),7.56(2H,d,aromatic),7.66(2H,d,aromatic),7.84(2H,d,aromatic)  
         [0178]    (b) (2R,4S)-4-Mesyloxy-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0179]    The compound (760 mg) which was prepared by example 1 (a) was dissolved in pyridine (6 mL), then DMAP (50 mg) and mesylchloride (279 mg) were slowly added at 0° C., followed by stirred for 3 h at room temperature. The reaction mixture was poured into 10% aq. HCl and acidified, then extracted with ethyl acetate (40 mL×2) followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated. The resulting solid was filtered, the object compound was obtained as a white solid (0.84 g).  
         [0180]    IR(cm −1 ): 2938,1734,1608,1350,1248,1161  
         [0181]    MS(m/z): 483(M + ),424,387,328,183(BP),140  
         [0182]    [0182] 1 H-NMR(CDCl 3 ): 1.90-1.94(1H,m,C5-H),2.03(1H,brd,C5-H),2.09-2.16(1H,m,C3-H), 2.71(1H,brd,C3-H),2.93(3H,s,Ms),3.54-3.61(1H,m,C6-H),3.58(3H,s,CO 2 CH 3 ), 3.81(1H, dd,C6-H),3.87(3H,s,OCH 3 ),4.85(1H,d,C2-H),5.05(1H,brS,C4-H), 7.01 (2H,d,aromatic),7.56(2H,d,aromatic),7.67(2H,d,aromatic),7.84(2H,d,aromatic)  
         [0183]    (c) (2R,4R)-4-Azide-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0184]    The compound (3 g) which was prepared by example 1 (b) was dissolved in DMF (20 mL), then sodium azide (605 mg) was added and stirred on overnight at 80° C. The reaction mixture was poured into ice water, then extracted with ethyl acetate (100 mL) followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated. The residue was purified by silica gel column chromatography using AcOEt:n-hexane (1:3), the object compound was obtained as a white solid (2.67 g).  
         [0185]    IR(cm −1 ): 2944,1740,1608,1521,1341,1290,1158  
         [0186]    MS(m/z): 430(M + ),402,343,183(BP), 139  
         [0187]    [0187] 1 H-NMR(CDCl 3 ): 1.49-1.58(1H,m,C5-H),1.74(1H,dt,C3-H),1.97(1H,brd,C5-H), 2.38(1H,brd,C3-H),3.29(1H,dt,C6-H),3.37-3.49(1H,m,C4-H),3.57(3H,s,CO 2 CH 3 ), 3.87(3H,s,OCH 3 ),3.94(1H,brd,C6-H),4.92(1H,d,C2-H),7.01 (2H,d,aromatic), 7.56(2H,d,aromatic),7.67(2H,d,aromatic),7.82(2H,d,aromatic)  
         [0188]    (d) (2R,4R)-4-Amino-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0189]    The compound (4.74 g) which was prepared by example 1 (c) was dissolved in MeOH/THF (3:2), 50 mL), then 5% Pd-C (500 mg) was added and stirred for 24 h under H 2  atmosphere. The reaction mixture was filtered on celite pad, and concentrated. The residue was purified by silica gel column chromatography using CHCl 3 :MeOH (20:1), the object compound was obtained as a pale yellow oil (4.33 g).  
         [0190]    IR(cm −1 ): 2938,1737,1290,1158,1038  
         [0191]    MS(m/z): 404(M + ),345,247,183,114,56(BP)  
         [0192]    [0192] 1 H-NMR(CDCl 3 ): 1.29-1.35(1H,m,C5-H),1.53(1H,dt,C3-H),1.81 (1H,brd,C3-H), 2.26-2.31(1H,m,C3-H),2.70-2.77(1H,m,C4-H),3.29(1H,dt,C6-H),3.55(3H,s,CO 2 CH 3 ), 3.86(3H,s,OCH 3 ),3.86-3.91(1H,m,C6-H),4.88(1H,d,C2-H),7.00(2H,d,aromatic), 7.55(2H,d,aromatic),7.66(2H,d,aromatic),7.82(2H,d,aromatic)  
         [0193]    (e) (2R,4R)-4-(4-methylpentanoyl)amino-2-methoxycarbonyl-1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine  
                         
 
         [0194]    The compound (500 mg) which was prepared by example 1 (d) and isocaproic acid (0.19 mL) were dissolved in DMF/CH 2 Cl 2  (5:1, 6 mL), then WSCDI (284 mg), N-methylmorpholine (0.16 mL), and DMAP (10 mg) were added at 0° C. and stirred on overnight. The reaction mixture was poured into water, then extracted with ethyl acetate (50 mL) followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated. The resulting solid was filtered, the object compound was obtained as a white solid (500 mg).  
         [0195]    [0195] 1 H-NMR(CDCl 3 ): 0.89(6H,d,CH 3 ), 1.38-1.67(5H,m,CH 2 ,CH,C5-H),2.00(1H,d,C3-H), 2.13(2H,m,CH 2 )2.42(1H,d,C3-H),3.35 (1H,dt,C6H),3.55 (3H,s,CO 2 CH 3 ),3.87(3H,s,OCH 3  ), 3.85-3.91 (2H,m,C4-H,C6-H),4.91 (1H,d,C2-H),5.24(1H,d,NH),7.01 (2H,d,aromatic), 7.56(2H,d,aromatic),7.66(2H,d,aromatic),7.82(2H,d,aromatic)  
         [0196]    (f) (2R,4R)-2—Carboxy4-(4-methylpentanoyl)amino-1-[4-(4-methoxyphenyl)benzene sulfonyl]-piperidine  
                         
 
         [0197]    The compound (181 mg) which was prepared by example 1 (e) was dissolved in THF/H 2 O (3:1, 4 mL), then lithium hydroxide monohydrate (30 mg) was added and stirred on overnight. After the reaction mixture was neutralized at 10% aq.HCl, it was extracted with chloroform (50 mL×2) followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated. The residue was purified by silica gel column chromatography using CHCl 3 :MeOH (10:1), the object compound was obtained as a white solid (175 mg).  
         [0198]    IR(cm −1 ): 3400,2944,1737,1608,1335,1251,1152,819  
         [0199]    MS(m/z): 470(M + -18),236,149,111,83,57(BP)  
         [0200]    [0200] 1 H-NMR(CDCl 3 ): 0.86(6H,d,CH 3 ),1.24-1.62 (5H,m,CH 2 ,CH,C5-H) ,1.78(1H,d,C3-H), 2.13(2H,m,CH 2 )2.40(1H,d,C3-H),3.21 (1H,m,C6-H),3.66(1H,m,C6-H),3.86(3H,s,OCH 3 ), 3.92(1H,m,C4-H),4.86(1H,d,C2-H),5.63(1H,d,NH),7.00(2H,d,aromatic),7.54(2H,d,aromatic), 7.60(2H,d,aromatic),7.80(2H,d,aromatic)  
         [0201]    Example: 2 (2R,4R)-2-Hydroxyamincarbonyl-1-[4-(4-methoxyphenyl)benzenesulfon-yl]-4-(4-methylpentanoylamino)-piperidine (Compound 49)  
                         
 
         [0202]    The compound (486 mg) which was prepared by example 1 and HOBT (228 mg) were dissolved in DMF/CH 2 Cl 2  (2:1, 3 mL), then WSCDI (286 mg) and N-methylmorpholine (0.33 mL) were added at 0° C. and stirred for 30 min, followed by addition of o-benzylhydroxyamine hydrochloride salt and further stirred on overnight. The reaction mixture was poured into a water and extracted with ethyl acetate (100 mL), followed by washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated.  
         [0203]    The resulting solid was filtered, a white solid (590 mg) was obtained. Subsequently, the compound (590 mg) was dissolved in THF (3 mL) then 5% Pd-C was added and stirred on overnight under H 2  atmosphere. The reaction mixture was filtered on celite pad, and concentrated. The residue was purified by silica gel column chromatography using CHCl 3 :MeOH (10:1), the object compound was obtained as a white solid (450 mg).  
         [0204]    IR(cm −1 ):3256,2944,1647,1521,1305,1251,1152,1032  
         [0205]    MS(m/z):442(M + -62),327,248,183,139,59(BP)  
         [0206]    [0206] 1 H-NMR(CDCl 3 ):0.87(6H,d,CH 3 ),1.23-1.81 (5H,m,CH 2 ,CH,C5-H),1.92(1H,d,C3-H), 2.11(2H,t,CH 2 )2.33(H,d,C3-H),3.44(H,m,C4-H),3.86(3H,s,OCH 3 ),3.92(1H,m,C6-H), 4.00(1H,m,C6-H),4.71(1H,m,C2-H),5.49(1H,d,NH),6.99(2H,d,aromatic), 7.56(2H,d,aromatic),7.67(2H,d,aromatic),7.84(2H,d,aromatic),9.92(1H,brs,NH)  
         [0207]    Example: 3 (2R,4R)-4-Acetylamino-2-carboxy-1-[4-(4-chlorophenyl)benzenesulfonyl]piperidine (Compound 31)  
         [0208]    (a) (2R,4R)-4-Acetylamino-2-methoxycarbonyl-1-(4-bromobenzenesulfonyl)-piperidine  
                         
 
         [0209]    (2R,4R)-4-Azide-2-methoxycarbonyl-1-(4-bromobenzenesulfonyl)-piperidine (1.97 g) was dissolved in THF/H 2 O (4:1, 16 mL), then triphenylphosphine (1.29 g) was added and stirred for 3 h at room temperature under Ar atmosphere. Subsequently, sat.Na 2 CO 3  (6 mL) was added and stirred for 30 min, then concentrated and extracted with chloroform (50 mL×2), dried (Na 2 SO 4 ), filtered, and concentrated. The crude product was dissolved in dichloromethane (10 mL), then triethylamine (1.02 mL), and acetic anhydride (0.69 mL) were added at 0° C., and stirred for 12 h. The reaction mixture was concentrated, then diluted with ethyl acetate (50 mL) followed by washed with 10% aq.citric acid, sat.NaHCO 3 , and brine. Subsequently, it was dried (Na 2 SO 4 ), filtered, and concentrated, then the residue was purified by silica gel column chromatography using AcOEt:n-hexane (1:5), the object compound was obtained as a pale yellow oil (1.60 g).  
         [0210]    IR(cm −1 ):2938,1740,1653,1545,1437,1338,1158,1089  
         [0211]    MS(m/z):419(M + ),361,300(BP),277,221,140,108,80,56  
         [0212]    [0212] 1 H-NMR(CDCl 3 ): 1.39(1H,m,C5-H),1.64(1H,m,C5-H),1.95(3H,s,Ac),2.00(1H,m,C6-H), 2.42(1H,m,C3-H),3.27(1H,td,C6-H),3.58(3H,s,CO 2 CH 3 ),3.84(2H,m,C4,C6-H), 4.87(1H,d,C2-H),5.40(1H,brd,NH),7.65(4H,m,aromatic)  
         [0213]    (b) (2R,4R)-4-Acetylamino-2-carboxy-1-[4-(4-chlorophenyl)benzenesulfonyl)-piperidine (Compound 31)  
                         
 
         [0214]    The compound (1.50 g) which was prepared by example 3 (a) was dissolved in acetonitrile (12 mL), then 4-chlorophenylboronic acid (839 mg), cesium fluoride (924 mg), and tetrakis(triphenylphosphine) palladium (207 mg) were added under Ar atmosphere, and stirred on overnight. The reaction mixture was poured into sat.Na 2 CO 3 , then extracted with ethyl acetate (50 mL×2), followed by dried (Na 2 CO 4 ), filtered, concentrated. The crude product was dissolved in THF/H 2 O (4:1, 10 mL), then lithium hydroxide monohydrate was added at room temperature and stirred on overnight. The reaction mixture was concentrated, then the residue was washed with ether and aqueous layer was neutralized at 10% aq.HCl, extracted with chloroform (50 mL×2), dried (Na 2 SO 4 ), filtered and concentrated. The resulting solid was filtered, the object compound was obtained as a white solid (1.27 g).  
         [0215]    IR(cm −1 ):3364,1728,1629,1545,1326,1152,1092,813,609  
         [0216]    ESI-MS(m/z): [M + H] + 437  
         [0217]    [0217] 1 H-NMR(CD 3 OD): 1.41 (1H,m,C5-H),1.65(1H,td,C5-H), 1.94(4H,m,C3-H,Ac), 2.42(1H,m,C3-H),3.37(1H,m,C4-H),3.85(2H,m,C6-H),4.88(1H,d,C2-H), 7.45 (2H,d,aromatic),7.54(2H,d,aromatic),7.66(2H,d,aromatic),7.88(2H,d,aromatic)  
         [0218]    Example: 4 (2R,4R)-4-Acethylamino-1-[4-(4-chlorophenyl)benzenesulfonyl]-2-hydroxyamino carbonyl-piperidine (Compound 72)  
                         
 
         [0219]    (COCl) 2 /CH 2 Cl 2  was added to DMF/CH 2 Cl 2  at −15° C. and stirred for 30 min. The reaction mixture was concentrated, then the residue was dissolved in CH 2 Cl 2  (2 mL) and the compound (145 mg) which was prepared by example 3 was added at 0° C. and stirred for 30 min. The reaction mixture was added other reaction mixture that hydroxylamine hydrochloride salt was dissolved in CH 2 Cl 2  then triethylamine was added at 0° C. and stirred for 15 min, and further stirred. After the reaction was completed, poured into H 2 O, extracted with chloroform (50 mL×2), dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using CHCl 3 : MeOH (10:1), the object compound was obtained as a white solid (115 mg).  
         [0220]    IR(cm −1 ):3298,3082,1641,1536,1332,1149,1092  
         [0221]    ESI-MS(m/z):[M + H]+452  
         [0222]    [0222] 1 H-NMR(DMSO) 1.23(1H,m,C5-H), 1.47(1H,m,C5-H), 1.84(4H,m,C3-H,Ac), 2.14(1H,m,C3-H),3.72(2H,t,C6-H),3.89(1H,m,C6-H),3.99(1H,m,C4-H),4.60(1H,d,C2-H), 7.70(2H,d,aromatic),7.81 (H,d,NH),7.93(2H,d,aromatic),7.96(2H,d,aromatic), 8.02(2H,d,aromatic),9.02(1H,brs,OH),10.8(1H,brs,NHOH)  
         [0223]    Example: 5 (2R,4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(pyridyl-2-yl)carbonyl amino-piperidine (Compound 33)  
         [0224]    (a) (2R,4R)-2-Methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(pyridyl-2-yl) carbonyl amino-piperidine  
                         
 
         [0225]    The compound (568 mg) which was prepared by example 1 (d) was dissolved in DMF/CH 2 Cl 2  (4:1, 5 mL), then picolinic acid (225 mg), WSCDI (403 mg), N-methylmorpholine (0.23 mL), and DMAP (10 mg) were added at 0° C. and stirred for 3 h. The reaction mixture was poured into H 2 O, then extracted with ethyl acetate (50 mL), washed with brine, dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using AcOEt:n-hexane (1:5), the object compound was obtained as a white solid (776 mg).  
         [0226]    IR(cm −1 ):3004,1740,1521,1338,1155  
         [0227]    [0227] 1 H-NMR(CDCl 3 ): 1.60(1H,m,C5-H), 1.83(1H,td,C5-H),2.11 (1H,m,C3-H),2.54(1H,m,C3-H), 3.44(1H,m,C6-H),3.59(3H,s,CO 2 CH 3 ),3.87(3H,s,OCH 3 ),3.96(1H,m,C6-H), 4.07(1H,m,C4-H),4.97(1H,d,C2-H),7.01 (2H,d,aromatic),7.44(1H,m,NH), 7.57(2H,d,aromatic),7.68(2H,d,aromatic),7.83-7.87(3H,m,aromatic,pyridine), 7.90(1H,d,pyridine),8.16(1H,d,pyridine),8.54(1H,d,pyridine)  
         [0228]    (b) (2R,4R)-2-Carbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(2-pyridinecarbonylamino)-piperidine (Compound 33)  
                         
 
         [0229]    The compound (713 mg) which was prepared by example 5 (a) was dissolved in THF/H 2 O (4:1, 5 mL), then lithium hydroxide monohydrate (88 mg) was added at room temperature, and stirred for 3 h. The reaction mixture was neutralized with aq.citric acid, and extracted with chloroform (50 mL×2), dried (Na 2 SO 4 ), filtered concentrated. The resulting solid was filtered, the object compound was obtained as a white solid (693 mg).  
         [0230]    IR(cm −1 ):3352,1734,1530,1358,1156  
         [0231]    ESI-MS(m/z):[M + H]+496  
         [0232]    [0232] 1 H-NMR(CDCl 3 ): 1.46(1H,m,C5-H), 1.80(1H,td,C5-H), 1.91 (1H,m,C3-H),2.54(1H,m,C3-H), 3.33(1H,m,C6-H),3.76(1H,m,C6-H),3.86(3H,s,OCH 3 ),4.18(1H,m,C4-H),4.96(1H,d,C2-H), 6.97(2H,d,aromatic),7.45(1H,dd,NH),7.53(2H,d,aromatic),7.62(2H,d,aromatic),7.81-7.85 (3H,m,aromatic,pyridine),8.09(1H,d,pyridine),8.13(1H,d,pyridine),8.54(1H,d,pyridine)  
         [0233]    Example: 6 (2R,4R)-2-Hydroxyaminocarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(pyridyl-2-yl) carbonylamino-piperidine (Compound 73)  
                         
 
         [0234]    The compound (250 mg) which was prepared by example 5 (compound 33) and HOBT (116 mg) were dissolved in DMF/CH 2 Cl 2  (4:1, 5 mL), then WSCDI (145 mg), N-methylmorpholine (0.17 mL), and o-benzylhydroxylamine hydrochloride salt (121 mg) were added at 0° C., and stirred on overnight. The reaction mixture was poured into H 2 O, then extracted with ethyl acetate (100 mL), washed with brine, dried (Na 2 SO 4 ), filtered, concentrated. The resulting solid was filtered, and dissolved in THF (5 mL). Subsequently, 5% Pd-C was added and stirred for 6 h at 40° C. under H 2  atmosphere. The reaction mixture was filtered on celite pad, and concentrated. The residue was purified by silica gel column chromatography using CHCl 3 :MeOH (50:1), the object compound was obtained as a white solid (237 mg).  
         [0235]    IR(cm −1 ):3346,1665,1521,1335,1155,1035,753  
         [0236]    ESI-MS(m/z):[M + H]+511  
         [0237]    [0237] 1 H-NMR(CDCl 3 ): 1.53(1H,m,C5-H),1.69(1H,m,C5-H),2.06(1l H,m,C3-H),2.43(1H,m,C3-H), 3.61 (1H,t,C6-H),3.86(3H,s,OCH 3 ),4.00(1H,m,C6-H),4.35(1H,m,C4-H),4.78(1H,d,C2-H), 7.00(2H,d,aromatic),7.43(1H,m,NH),7.57(2H,d,aromatic),7.69(2H,d,aromatic),7.83-7.93 (5H,m,aromatic,pyridine),8.21(1H,d,NH),8.50(1H,d,pyridine),10.3(1H,s,OH)  
         [0238]    Example: 7 (2R,4R)-4-Benzylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzene-sulfonyl]-piperidine (Compound 14)  
         [0239]    (a) (2R,4R)-4-Benzylamino-2-methylcarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0240]    The compound (850 mg) which was prepared by example 1 (d) was dissolved in MeOH (5 mL), then benzaldehyde (1.11 g) was added at room temperature, and stirred for 30 min. After cooled at 0° C., NaBH 4  (224 mg) was added and stirred for 10 min, following stirred for 10 min at room temperature. The reaction mixture was poured into brine, then extracted with ethyl acetate (10 mL×2), dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using ethyl acetate:n-hexan (2:1), the object compound was obtained as a white solid (535 mg).  
         [0241]    IR(cm −1 ):1743,1338,1254,1158,1095,753,624  
         [0242]    MS(m/z):494(M + ),435,315,247,183,146,91 (BP)  
         [0243]    [0243] 1 H-NMR(CDCl 3 ): 1.31-1.38(1H,m,C5-H),1.55(1H,dt,C3-H),1.88(1H,brd,C5-H), 2.69(1H,brd,C3-H),2.54-2.60(1H,m,C4-H),3.26(1H,dt,C6-H),3.54(3H,s,CO 2 CH 3 ), 3.77(2H,s,benzyl positopn),3.87(3H,s,OCH 3 ),3.90(1H,brd,C6-H),4.89(1H,d,C2-H), 7.00(2H,d,aromatic),7.21-7.34(5H,m,aromatic),7.55(2H,d,aromatic), 7.65(2H,d,aromatic),7.82(2H,d,aromatic)  
         [0244]    (b) (2R,4R)-4-Benzylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 14)  
                         
 
         [0245]    The compound (100 mg) which was prepared by example 7 (a) was dissolved in MeOH/THF (2:1), 1.5 mL), then 1 N aq.LiOH (0.4 mL) was added at 0° C., and stirred for 2 h at room temperature. The reaction mixture was neutralized at 10% aq.HCl, then resulting solid was filtered, the object compound was obtained as a white solid (68 mg).  
         [0246]    IR(cm −1 ):3424,1608,1335,1293,1149  
         [0247]    MS(m/z):462(M + -18),371,248,215,183,139,91 (BP),  
         [0248]    [0248] 1 H-NMR(DMSO): 1.16-1.22(1H,m,C5-H), 1.44-1.52(1H,m,C3-H),2.02(1H,brd,C5-H), 2.38(1H,brd,C3-H),2.84-2.88(1H,m,C4-H),3.42-3.53(1H,m,C6-H),3.73-3.75 (2H,m,benzyl positopn),3.80(3H,s,OCH 3 ),3.97-4.02(1H,m,C6-H),4.48(1H,brs,C2-H), 7.02(2H,d,aromatic),7.27-7.43(5H,m,aromatic),7.58(2H,d,aromatic), 7.69(2H,d,aromatic),7.78(2H,d,aromatic)  
         [0249]    Example: 8 (2R,4R)-4-Benzylamino-2-hydroxyaminocarbonyl 1-[4-(4-methoxyphenyl) benzenesulfonyl]-piperidine (Compound 56)  
                         
 
         [0250]    Hydroxylamine hydrochloride salt (200 mg) was dissolved in MeOH (2 mL), then potassium hydroxide (250 mg)/MeOH (1.3 mL) was added at 0° C., and stirred for 1 h. After filtered insoluble material, the filterate was added to the solution that the compound (200 mg) which was prepared by example 7 (a) was dissolved in THF (2 mL), at 0° C., and stirred for 6 h at room temperature. The reaction mixture was neutralized with aq.HCl, then extracted with THF (10 mL×2), dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using CHCl 3 : MeOH (10:1), the object compound was obtained as a white solid (51 mg).  
         [0251]    IR(cm −1 ):3370,1668,1485,1335,1251,1155,1035  
         [0252]    MS(m/z):494(M + -1),463,435,371,315,247,183,139,91 (BP)  
         [0253]    [0253] 1 H-NMR(CD 3 OD): 1.51-1.56(1H,m,C5-H), 1.71(1H,dt,C3-H),2.22(1H,brd,C5-H), 2.49(1H,dd,C3-H),3.59(1H,dt,C4-H),3.68-3.74(1H,m,C6-H),3.89(3H,s,OCH 3 ), 4.11 (1H,brd,C6-H),4.22(2H,s,benzyl positopn),4.80(1H,d,C2-H),7.09(2H,d,aromatic), 7.46-7.50(5H,m,aromatic),7.70(2H,d,aromatic),7.86(2H,d,aromatic),7.94(2H,d,aromatic)  
         [0254]    Example: 9 (2R,4R)-2-Carboxy4-(4-methylpentanoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 7)  
         [0255]    (a) (2R,4R)-2-Methoxycarbonyl-4-(4-methylpentanoylamino)-1-(2-thiophenesulfonyl)-piperidine  
                         
 
         [0256]    (2R,4R)-2-Methoxycarbonyl-4-(4-methylpentanoylamino)-piperidine (250 mg) was dissolved in CH 2 Cl 2  (5 mL), then Et 3 N (0.2 mL) and 2-thiophenesulfonyl chloride (267 mg) were added at 0° C., and stirred for 1 h. The reaction mixture was poured into aq.citric acid, then extracted with ethyl acetate (50 mL), washed with brine, dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:10), the object compound was obtained as a white solid (191 mg).  
         [0257]    IR(cm −1 ):3256,1740,1638,1554,1455,1338,1227,1152  
         [0258]    MS(m/z):401(M + ),255,228, 140(BP), 116,80,55  
         [0259]    [0259] 1 H-NMR(CDCl 3 ):0.89(6H,d,CH 3 ), 1.37-1.67(5H,m,CH 2 ,CH,C5-H),2.02(1H,d,C3-H), 2.13(2H,t,CH 2 )2.42(1H,dd,C3-H),3.39(1H,dt,C4-H),3.602and3.604(total3H,eachs,CO 2 CH 3 ), 3.84-3.93(2H,m,C4-H,C6-H),4.89(1H,d,C2-H),5.25(1H,d,NH),7.09(1H,m,thiophene), 7.55-7.59(2H,m,thiophene)  
         [0260]    (b) (2R,4R)-2-Carboxy-4-(4-methylpentanoylamino)-1-(2-thiophenesulfonyl)-piperidine (Compound 7)  
                         
 
         [0261]    The compound (536 mg) which was prepared by example 9 (a) was dissolved in THF/H 2 O (2:1, 6 mL), then lithium hydroxide monohydrate (88 mg) was added, and stirred for 2 h. The reaction mixture was neutralized with aq.citric acid, then extracted with chloroform (50 mL×2), dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using CHCl 3 :MeOH (5:1), the object compound was obtained as a white solid (357 mg).  
         [0262]    IR(cm −1 ):3364,1737,1626,1545,1338,1149  
         [0263]    MS(m/z):387(M + ),27 1,228,126(BP),82,55  
         [0264]    [0264] 1 H-NMR(CDCl 3 ):0.89(6H,d,CH 3 ), 1.30-1.66(5H,m,CH 2, CH,C5-H), 1.90(1H,d,C3-H), 2.16(2H,m,CH 2 )2.43(1H,d,C3-H),3.33(1H,m,C4-H),3.77(1H,m,C6-H),3.95(1H,m,C6-H), 4.87(1H,d,C2-H),5.59(1H,d,NH),7.05(1H,dd,thiophene),7.53-7.57(2H,m,thiophene)  
         [0265]    Example: 10 (2R,4R)-2-Hydroxyaminocarbonyl-4-(4-methylpentanoylamino)-1-(2-thiophene-sulfonyl)-piperidine (Compound 51)  
                         
 
         [0266]    The compound (200 mg) which was prepared by example 9 (compound 7) and HOBT (95 mg) were dissolved in DMF/CH 2 Cl 2  (1:1, 4 mL), then WSCDI (119 mg) and N-methylmorpholine (0.07 mL) were added at 0° C., and stirred for 1 h, following addition of hydroxylamine hydrochloride salt (54 mg) and N-methylmorpholine (0.08 mL), and further stirred for 6 h. The reaction mixture was poured into H 2 O, then extracted with ethyl acetate (50 mL), washed with brine, dried (Na 2 SO 4 ), filtered, concentrated. The residue was purified by silica gel column chromatography using CHCl 3 : MeOH (10:1), the objected compound was obtained as a white solid (40 mg).  
         [0267]    IR(cm −1 ):3280,1644,1539,1341,1152  
         [0268]    MS(m/z):338(M + -14),358,301,271,228,196,148,116(BP),82,56  
         [0269]    [0269] 1 H-NMR(CDCl 3 ):0.86(6H,d,CH 3 ), 1.26-1.53(5H, m,CH 2 ,CH,C5-H), 1.96(1H,d,C3-H), 2.11 (2H,m,CH 2 )2.22(1H,d,C3-H),3.59(1H,m,C4-H),3.90(1H,m,C6-H),4.03(1H,m,C6-H), 4.69(1H,m,C2-H),6.08(1H,m,NH),7.11(1H,m,thiophene),7.60-7.63(2H,m,thiophene), 8.29(1H,brs,NH), 10.4(1H,brs,OH)  
         [0270]    Example: 11 (2R,4R)-2-Carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-4-(pyridin-N-oxide-2-yl) carbonylamino-piperidine (Compound 39)  
                         
 
         [0271]    The compound (70 mg) which was prepared by example 5 was dissolved CH 2 Cl 2  (5 mL), then mCPBA (73 mg) was added and stirred on overnight at 60° C. The reaction mixture was poured into sat.Na 2 S 2 O 3 , then extracted with CHCl 3  (50 mL), dried (Na 2 SO 4 ), filtered, concentrated. The resulting solid filtered, the object compound was obtained as a white solid (43 mg).  
         [0272]    IR(cm −1 ):3406,1725,1629,1593,1359,1212,1152,1038  
         [0273]    TSP-MS(m/z):[M + H]+512,[M−H]-510  
         [0274]    [0274] 1 H-NMR(DMSO): 1.38(1H,m,C5-H), 1.69(1H,m,C5-H),2.02(1H,m,C3-H),2.48(1H,m,C3-H), 3.58(1H,m,C4-H),3.88(1H,m,C6-H),3.94(3H,s,OCH 3 ),4.01 (1H,m,C6-H),4.77(1H,m,C2-H), 7.19(2H,d,aromatic),7.71 (2H,m,pyridine),7.84(2H,d,aromatic),7.95(2H,d,aromatic), 7.99(2H,d,aromatic),8.28(1H,dd,pyridine),8.51(1H,m,pyridine), 11.2(1H,d,NH)  
         [0275]    Example: 12 (2R,4R)-4-Acetylamino-2-carboxy-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 24)  
         [0276]    (a) (2R,4R)-4-Acetylamino-2-methoxycarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine  
                         
 
         [0277]    (2R,4R)-4-amino-2-methylcarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine (1.38 g) was dissolved in CH 2 Cl 2  (10 mL), then Et 3 N (0.88 mL) and acetic anhydride (0.59 mL) were added at 0° C., and stirred for 1 h. The reaction mixture was concentrated, then diluted with ethyl acetate (50 mL), and washed with 10% aq.citric acid, sat.NaHCO 3 , and brine, respectively. The organic layer was dried (Na 2 SO 4 ), filtered, concentrated, then the residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:5), the object compound was obtained as a colorless oil (1.56 g).  
         [0278]    IR(cm −1 ):3364,1725,1599,1497,1332,1260,1089,555  
         [0279]    MS(m/z):338[M + -18]252,214,171,140,107,80(BP)55  
         [0280]    [0280] 1 H-NMR(CDCl 3 ): 1.35(1H,m,C5-H),1.61 (1H,td,J=12.7,5.9 Hz,C5-H),1.86(1H,m,C3-H), 1.96(3H,s,Ac),2.40(1H,m,C3-H),3.23(1H,m,C6-H),3.71 (1H,m,C6-H),3.85(3H,s,Ome), 3.90(1H,m,C4-H),4.83(1H,d,J=5.4 Hz,C2-H),5.86(1H,d,J=8.3 Hz,NH), 6.93(2H,d,J=8.8 Hz,aromatic),7.74(2H,d,J=8.8 Hz,aromatic)  
         [0281]    (b) (2R,4R)-4-Acetylamino-2-carboxy-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 24)  
                         
 
         [0282]    The compound (1.50 g) which was prepared by example 12 (a) was carried out same reaction of example 3 (b), thus the object compound was a white solid (1.30 g).  
         [0283]    Example: 13 (2R,4R)-4-Acetylamino-2-hydroxyaminocarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine (Compound 66)  
                         
 
         [0284]    The compound (670 mg) which was prepared by example 12 was carried out same reaction of example 2, thus the object compound was obtained as a colorless solid (265 mg).  
         [0285]    IR(cm −1 ):3262,2926,1659,1545,1497,1260,1149,558  
         [0286]    MS(m/z):327[M + -44]284,252,171,139,97(BP)77,56  
         [0287]    [0287] 1 H-NMR(DMSO): 1.17(1H,m,C5-H),1.42(1H,m,C5-H),1.80(1H,m,C3-H),1.84(3H,s,Ac), 1.96(1H,m,C3-H),3.66(1H,m,C6-H),3.81(1H,m,C6-H),3.96(4H,s,OmeandC4-H), 4.53(1H,d,J=5.4 Hz,C2-H),7.21 (2H,d,J=8.8 Hz,aromatic),7.79(1H,d,J=8.3 Hz,NH), 7.82(2H,d,J=8.8 Hz,aromatic)8.99(1H,s,CONH),10.8(1H,s,OH)  
         [0288]    Example: 14 (2R,4S)-4-Acetylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 44)  
         [0289]    (a) (2R,4R)-4-Acetoxy-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0290]    The compound (10.67 g) which was prepared by example 1 (b) was dissolved in toluene (110 mL), then cesium acetate (42.4 g) and 18-crown-6-ether (5.84 g) were added, and reflux for 3 h. The reaction mixture was filtered and concentrated, then the residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:4), the object compound was obtained as a colorless solid (3.04 g).  
         [0291]    IR(cm −1 ):2938,2830,1740,1605,1518,1440,1341,1290,1155  
         [0292]    MS(m/z):447[M + ]-373,328,291,247,183,140,79(BP)  
         [0293]    [0293] 1 H-NMR(CDCl 3 ): 1.53-1.61 (1H,m,C5-H), 1.79-1.86(1H,m,C5-H),2.02(4H,S+m,Ac,C3-H), 2.38-2.42(1H,m,C3-H),3.35(1H,dt,C6-H),3.57(3H,s,CO 2 CH 3 ),3.87(3H,s,OCH 3 ), 3.89-3.93(1H,m,C6-H),4.73-4.79(1H,m,C4-H),4.92(1H,d,J=6.0 Hz,C2-H), 7.01,7.56(4H,ABq,aromatic)7.67,7.83(4H,ABq,aromatic)  
         [0294]    (b) (2R,4R)-4-Hydroxy-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0295]    The compound (3.04 g) which was prepared by example 14 (a) was dissolved in MeOH (40 mL), then sodium methoxide (324 mg) was added, and stirred for 1 h at room temperature. Furthermore amberlite IR-120 (2.0 g) was added, and stirred for 1 h. Subsequently, the reaction mixture was filtered and concentrated, then the residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:1), the object compound was obtained as a colorless solid (1.85 g).  
         [0296]    IR(cm −1 ):3526,2944,1737,1605,1521,1440,1338,1152  
         [0297]    MS(m/z):405[M + ]373,329,247,183,139,114,82,55(BP)  
         [0298]    [0298] 1 H-NMR(CDCl 3 ): 1.45-1.53(1H,m,C5-H),1.65-1.72(1H,m,C5-H),1.92-1.96(1H,m,C3-H), 2.38-2.42(1H,m,C3-H),3.29(1H,dt,J=9.2 Hz,C4-H),3.57(3H,s,CO 2 CH 3 ), 3.69-3.71(1H,m,C6-H),3.87(3H,s,OCH 3 ),3.88-3.93(1H,m,C6-H),4.90(1H,d,J=6.0 Hz,C2-H), 7.00,7.58(4H,ABq,aromatic)7.65,7.84(4H,ABq,aromatic)  
         [0299]    (c) (2R,4R)-4-Mesyloxy-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0300]    The compound (1.85 g) which was prepared by example 14 (b) was carried out same reaction of example 1 (b), thus the object compound was obtained as a colorless solid (1.78 g).  
         [0301]    IR(cm −1 ):3406,2938,1740,1605,1518,1485,1341,1293,1155  
         [0302]    MS(m/z):483[M + ]456,424,373,328,277,247,214,183(BP) 140,115,80,55  
         [0303]    [0303] 1 H-NMR(CDCl 3 ): 1.76-1.80(1H,m,C5-H),1.93-2.00(1H,m,C5-H),2.15-2.19(1H,m,C3-H), 2.53-2.57(1H,m,C3-H),3.01 (3H,s,Ms),3.31 (1H,dt,J=9.2 Hz,C6-H),3.59(3H,s,CO 2 CH 3 ), 3.87(3H,s,OCH 3 ),3.94-3.97(1H,m,C6-H),4.71-4.77(1H,m,C4-H),4.93(1H,d,J=6.0 Hz,C2-H), 7.01,7.56(4H,ABq,J=8.8 Hz,aromatic)7.67,7.82(4H,ABq,J=8.4 Hz,aromatic)  
         [0304]    (d) (2R,4S)4-Azide-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine  
                         
 
         [0305]    The compound (1.78 g) which was prepared by example 14 (c) was carried out same reaction of example 1 (c), thus the object compound was obtained as a colorless solid (1.45 g).  
         [0306]    IR(cm −1 ):3424,2944,2104,1746,1605,1518,1341,1155  
         [0307]    MS(m/z):430[M+]371,247,183(BP)139,95,55  
         [0308]    [0308] 1 H-NMR(CDCl 3 ): 1.78-1.82(2H,m,C5-H),2.05-2.10,2.52-2.55(2H,eacheachm,C3-H), 3.44(1H,dt,J=9.2 Hz,C6-H),3.62(3H,s,CO 2 CH 3 ),3.69,3.71  
         [0309]    (e) (2R,4S)-4-Acetylamino-2-methoxycarbonyl-1-[4-(4-methoxyphenyl)benzene sulfonyl]-piperidine  
                         
 
         [0310]    The compound (0.20 g) which was prepared by example 14 (d) was dissolved in pyridine (1.5 mL), then thioacetic acid (1.5 mL) was added at 0° C., and stirred on overnight at room temperature. The reaction mixture was concentrated, then the residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:1), the object compound was obtained as a colorless solid (0.19 g).  
         [0311]    IR(cm −1 ):3400,2920,1740,1650,1521,1488,1338,1293,1158  
         [0312]    MS(m/z):446[M + ]381,342,313,281,252,206,175,149(BP) 119,85,55  
         [0313]    [0313] 1 H-NMR(CDCl 3 ): 1.76-1.84(1H,m,C5-H),1.89(3H,s,Ac),1.99-2.03(1H,m,C5-H), 2.19-2.24(1H,m,C3-H),3.45-3.50(1H,dt,C3-H),3.62(3H,s,CO 2 CH 3 ),3.63-3.74(1H,m,C4-H), 3.87(3H,s,OCH 3 ),3.85-3.91 (1H,m,C6-H),4.16-4.19(1H,m,C6-H),4.64-4.67(1H,m,C2-H), 6.14-6.17(1H,m,NH),7.01,7.56(4H,ABq,aromatic)7.65,7.85(4H,ABq,aromatic)  
         [0314]    (f) (2R,4S)4-Acetylamino-2-carboxy-1-[4-(4-methoxyphenyl)benzenesulfonyl]-piperidine (Compound 44)  
                         
 
         [0315]    The compound (190 mg) which was prepared by example 14 (e) was carried out same reaction of example 1 (f), thus the object compound was obtained as a colorless solid (160 mg).  
         [0316]    IR(cm −1 ):3412,2914,1725,1608,1338,1251,1155,1092  
         [0317]    MS(m/z):433 ┌M + +1┘385,328,277,248,216,184,139,108,81 (BP)55  
         [0318]    [0318] 1 H-NMR(CDCl 3 ): 1.17-1.32(1H,m,C5-H),1.57-1.68(1H,m,C5-H),1.98(3H,s,Ac), 2.39-2.48(1H,m,C3-H),2.86(1H,m,C3-H),3.24-3.30(1H,m,C4-H),3.60(1H,m,C6-H), 3.73-3.76(1H,m,C6-H),3.88(3H,s,OCH 3 ),4.76(1H,d,J=5.4 Hz,C2-H), 6.99-7.06(2H,m,aromatic)7.52-7.85(6H,m,aromatic),8.40(1H,brm,NH)  
         [0319]    Example: 15 (2R,4S)-4-Acetylamino-2-hydroxyaminocarbonyl-1-[4-(4-methoxy-phenyl)benzenesulfonyl]-piperidine (Compound 82)  
                         
 
         [0320]    The compound (120 mg) which was prepared by example 14 was carried out same reaction of example 2, thus the object compound was obtained as a colorless solid (68 mg).  
         [0321]    IR(cm −1 ):3424,2914,1638,1488,1335,1251,1152,1092  
         [0322]    MS(m/z):447[M + ]416,371,328,248,216,183,140,115,82(BP)48  
         [0323]    [0323] 1 H-NMR(CD 3 OD): 1.11-1.38(2H,m,C5-H),1.84(1H,m,C3-H),1.88(3H,s,Ac), 2.28-2.31 (1H,m,C3-H),3.42-3.49(1H,m,C4-H),3.83(1H,m,C6-H),3.88(3H,s,OCH 3 ), 3.92(1H,m,C6-H),4.69(1H,d,J=5.4 Hz,C2-H),6.87(1H,d,J=7.3 Hz,NH), 7.02,7.58(4H,ABq,J=8.8 Hz,aromatic)7.72,7.86(4H,ABq,J=8.3 Hz,aromatic)  
         [0324]    Example: 16 (2R,4R)-2-Carboxy-1-(4-methoxybenzenesulfonyl)-4-(pyridyl-2-yl) carbonylamino-piperidine (Compound 68)  
         [0325]    (a) (2R,4R)-2-Methoxycarbonyl-1-(4-methoxybenzenesulfonyl)-4-(pyridyl-2-yl)carbonyl amino-piperidine  
                         
 
         [0326]    (2R,4S)-4-Amino-2-methoxycarbonyl-1-(4-methoxybenzenesulfonyl)-piperidine (800 mg) was dissolved in DMF (5 mL), then WSCDI (610 mg), Et 3 N (0.44 mL), 2-pyridinecarboxylic acid (390 mg), and DMAP (80 mg) were added at 0° C., and stirred for 16 h. The reaction mixture was diluted with ethyl acetate (50 mL), then washed with 10% aq.citric acid, sat.NaHC 3 , and brine, respectively. The organic layer was dried (Na 2 SO 4 ), filtered, and concentrated, then the residue was purified by silica gel column chromatography using ethyl acetate:n-hexane (1:1), the object compound was obtained as a colorless oil (900 mg).  
         [0327]    IR(cm −1 ):3364,2938,1734,1662,1593,1458,1338,1254,1149,726  
         [0328]    MS(m/z):434[M + ]374,312,252,208,180,107  
         [0329]    [0329] 1 H-NMR(CDCl 3 ):1.56(1H,m,C5-H), 1.81 (1H,m,C5-H),2.07(1H,m,C3-H),2.50(1H,m,C3-H), 3.39(1H,dt,J=13.2 Hz,C6-H),3.61(3H,S,CO 2 CH 3 ),3.87(3H,s,OCH 3 ),3.91 (1H,m,C6-H), 4.05(1H,m,C4-H),4.92(1H,d,J=5.4 Hz,C2-H),6.97(2H,ABq,J=8.8 Hz,aromatic), 7.43(1H,m,pyridine),7.75(2H,ABq,J=8.8 Hz,aromatic),7.84(1H,m,pyridine), 7.90(1H,d,J=7.8 Hz,pyridine),8.15(1H,d,J=7.8 Hz,pyridine),8.54(1H,d,J=4.9 Hz,NH)  
         [0330]    (b) (2R,4R)-2—Carboxy-1-(4-methoxybenzenesulfonyl)-4-(pyridyl-2-yl) carbonylamino-piperidine (Compound 68)  
                         
 
         [0331]    The compound (900 mg) which was prepared by example 16 (a) was carried out same reaction of example 1 (f), thus the object compound was obtained as a colorless solid (820 mg).  
         [0332]    IR(cm −1 ):3340,2932,1728,1590,1326,1266,1095,558  
         [0333]    MS(m/z):419[M + ]310,252,202,171,126,80,52  
         [0334]    [0334] 1 H-NMR(CDCl 3 ):1.52(1H,m,C5-H), 1.80(1H,m,C5-H), 1.97(1H,m,C3-H),2.55(1H,m,C3-H), 3.31 (1H,dt,J=13.2 Hz,C6-H),3.75 (1H,m,C6-H),3.83(3H,s,OCH 3 ),4.20(1H,m,C4-H), 4.93(1H,d,J=5.4 Hz,C2-H),6.93(2H,ABq,J=9.3 Hz,aromatic),7.47(1H,m,pyridine), 7.77(2H,ABq,J=9.3 Hz,aromatic),7.86(1H,dt,J=7.8,7.3 Hz,pyridine),8.14(1H,m,pyridine), 8.55(1H,d,J=8.8 Hz,NH)  
         [0335]    Example: 17 (2R,4R)-2-Hydroxyaminocarbonyl-1-(4-methoxybenzene sulfonyl)-4-(pyridyl-2-yl)carbonylamino-piperidine (Compound 69)  
                         
 
         [0336]    The compound (160 mg) which was prepared by example 16 was carried out same reaction of example 2, thus the object compound was obtained as a colorless solid (90 mg).  
         [0337]    IR(cm −1 ):3214,2908,1656,1524,1461,1335,1257,1149,1023,558  
         [0338]    MS(m/z):434[M + ]413,374,341,284,253,204,177,157,131,99,66  
         [0339]    [0339] 1 H-NMR(CD 3 OD):1.48(2H,m,C5-H),2.00(1H,m,C3-H),2.40(1H,m,C3-H),3.54(1H,m,C6-H), 3.80(3H,s,OCH 3 ),3.94(1H,m,C6-H),4.30(1H,m,C4-H),4.73(1H,d,J=5.4 Hz,C2-H), 6.97(2H,ABq,J=8.8 Hz,aromatic),7.42(1H,m,pyridine),7.77(2H,ABq,J=8.8 Hz,aromatic), 7.84(1H,t,J=7.8 Hz,pyridine),8.18(1H,d,J=7.8 Hz,pyridine),8.50(1H,d,J=4.4 Hz,pyridine), 10.31(1H,s,OH)  
                                                                 Comp. No.   m.p. (° C.)                                        1   147˜149           2   95˜97           3   240˜243           4   &gt;250           5   102˜104           6   205˜210           7   72˜73           8   185˜186           9   233˜235           10   150˜151           11   42˜43           12   84˜85           13   61˜62           14   &gt;250           15   oil           16   164˜166           17   228˜230           18   60˜62           19   254˜256           20   &gt;250           21   235˜238           22   210˜211           23   170˜172           24   90˜92           25   120˜121           26   149˜150           27   &gt;250           28   252˜253           29   238˜239           30   185˜186           31   243˜245           32   245˜246           33   226˜227           34   228˜230           35   193˜195           36   258˜259           37   237˜238           38   152˜154           39   220˜223           40   100˜102           41   150˜152           42   240˜244           43   94˜96           44   148˜149           45   82˜84           46   60˜62           47   176˜178           48   181˜182           49   106˜108           50   130˜135           51   93˜95           52   85˜86           53   90˜91           54   88˜89           55   94˜96           56   158˜160           57   88˜90           58   170˜172           59   88˜90           60   160˜162           61   91˜93           62   144˜146           63   125˜129           64   178˜179           65   155˜156           66   118˜120           67   110˜112           68   139˜141           69    99˜100           70   131˜132           71   113˜114           72   188˜189           73   135˜137           74   145˜148           75   164˜165           76   177˜179           77   177˜178           78   106˜108           79   135˜136           80   190˜192           81   108˜110           82   198˜199           83   162˜163           84   110˜111           85   153˜154           86   183˜184           87   243˜245           88   180˜182           89   239˜240